

References

1. WHO, *Global tuberculosis control: epidemiology, strategy, financing : WHO report*. WHO/HTM/TB/2009.411, 2009.
2. Crubezy, E., Ludes, B., Poveda, J., Clayton, J., Crouau-Roy, B., Montagnon D., *Identification of Mycobacterium DNA in an Egyptian Pott's disease of 5 400 years old*. C. R. Acad. Sci. Paris, Sciences de la vie / Life Sciences, 1998. **321**: p. 941-951.
3. Donoghue, H.D., Lee, O.Y-C., Minnikin, D.E., Besra, G.S., Taylor, J.H., Spigelman, M., *Tuberculosis in Dr Granville's mummy: a molecular re-examination of the earliest known Egyptian mummy to be scientifically examined and given a medical diagnosis*. Proc R Soc B, 2010. **277**: p. 51-56.
4. Koch, R., *Die Aetiologie der Tuberkulose*. Berliner Klinischen Wochenschrift, 1882. **15**: p. 221-230.
5. Tuberculosis, *In Encyclopædia Britannica*. 2010, www.britannica.com/EBchecked/topic/608235/tuberculosis/253299/Tuberculosis-through-history.
6. Mccarthy, O.R., *The key to the sanatoria*. J R Soc Med, 2001. **94**: p. 413-417.
7. Andrews, J., Basu, S., Scales, D., Smith-Rohrberg Maru, D., *XDR-TB in South Africa*. PLOS Medicine, 2007. **4**: p. 770-771.
8. Wise, J., *Southern Africa is moving swiftly to combat the threat of XDR-TB*. Bull World Health Organ, 2006. **84**: p. 924-925.
9. Calver, A.D., Falmer, A.A., Murray, M., Strauss, O.J., Streicher, E.M., Hanekom, M., Liversage, T., Masibi, M., van Helden, P.D., Warren, R.M., Victor, T.C., *Emergence of increased resistance and extensively drug-resistant tuberculosis despite treatment adherence, South Africa*. Emerg Infect Dis, 2010. **16**(2): p. 264-271.
10. Department of Health. *The South African national tuberculosis control programme practical guidelines*. 2004.
11. Dick, T., *Dormant tubercle bacilli: the key to more effective TB chemotherapy?* J Antimicrob Chemother, 2001. **47**: p. 117-118.
12. Parrish, N.M., Dick, J.D., Bishai, W.R., *Mechanisms of latency in Mycobacterium tuberculosis*. Trends Microbiol, 1998. **6**: p. 107-112.
13. Barry 3rd, C.E., Boshoff, H.I., Dartois, V., Dick, T., Ehrt, S., Flynn, J., Schnappinger, D., Wilkinson, R.J., Young, D., *The spectrum of latent tuberculosis: rethinking the biology and intervention strategies*. Nature Rev, 2009. **7**: p. 845-855.
14. Korf, J., Stoltz, A., Verschoor, J.A., De Baetselier, P., Grooten, J., *The Mycobacterium tuberculosis cell wall component mycolic acid elicits pathogen-associated host innate immune responses*. Eur J Immunol, 2005. **35**: p. 890-900.
15. Cardona, P.J., *RUTI: A new chance to shorten the treatment of latent tuberculosis infection*. Tuberculosis, 2006. **86**: p. 272-289.
16. Sosnik, A., Carcaboso, A.M., Glisoni, R.J., Moretton, M.A., Chiappetta, D.A., *New old challenges in tuberculosis: Potentially effective nanotechnologies in drug delivery*. Adv Drug Deliv Rev, 2009. **62**: p. 547-559.
17. Nardell, E.A., *The Merck Manual Online*. 2009, www.merck.com/mmpe/sec14/ch179/ch179b.html.

References

18. Dye, C., *Global epidemiology of tuberculosis*. Lancet, 2006. **367**: p. 938-940.
19. Zignol, M., Hosseini, M.S., Wright, A., Lambregts-van Weezenbeek, C., Nunn, P., Watt, C.J., Williams, B.G., Dye, C., *Global incidence of multidrug-resistant tuberculosis*. J Infect Dis, 2006. **194**: p. 479-485.
20. McIlleron, H., Meintjes, G., Burman, W.J., Maartens, G., *Complications of antiretroviral therapy in patients with tuberculosis: Drug interactions, toxicity, and immune reconstitution inflammatory syndrome*. J Infect Dis, 2007. **196**: p. S63-75.
21. Rastogi, N., Goh, K.S., Horgen, L., Barrow W.W., *Synergistic activities of antituberculosis drugs with cerulenin and trans-cinnamic acid against Mycobacterium tuberculosis*. FEMS Immunol Med Microbiol, 1998. **21**: p. 149-157.
22. Maartens, G., Wilkinson, R.J., *Tuberculosis*. Lancet, 2010. **370**: p. 2030-43.
23. Barry 3rd, C.E., *New horizons in the treatment of tuberculosis*. Biochem Pharmacol, 1997. **54**(11): p. 1165-1172.
24. Ramsden, J.J., *What is nanotechnology?* . Nanotechnology Perceptions, 2005. **1**: p. 3-17.
25. Wagner, V., Dullaart, A., Bock, A.,Zweck, A., *The emerging nanomedicine landscape*. Nat Biotechnol, 2006. **10**: p. 1211-1217.
26. Bangham, A.D., Standish, M.M., Watkins, J.C., *Diffusion of univalent ions across the lamellae of swollen phospholipids*. J Mol Biol, 1965. **13**: p. 238-252.
27. Langer, R., Folkman, J., *Polymers for the sustained release of proteins and other macromolecules*. Nature, 1976. **263**: p. 797-800.
28. Farokhzad, O.C., Langer, R., *Impact of nanotechnology on drug delivery*. ACSNANO, 2009. **3**: p. 16-20.
29. Panyam, J., Zhou, W., Prabha, S., Sahoo, S.K., Labhasetwar, V., *Rapid endo-lysosomal escape of poly(DL-lactide-coglycolide) nanoparticles: implications for drug and gene delivery*. FASEB J, 2002. **16**: p. 1217-1226.
30. Alexis, F., Pridgen, E., Molnar, L.K., Farokhzad, O.C., *Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles*. Mol Pharmaceutics, 2008. **5**: p. 505-515.
31. Storm, G., Belliot, S.O., Daemen, T., Lasic, D.D., *Surface modification of nanoparticles to oppose uptake by the mononuclear phagocytic system*. Adv Drug Deliv Rev, 1995. **17**: p. 31-48.
32. Gomes, A.J., Faustino, A.S., Machado, A.E., Zaniquelli, M.E., de Paula Rigoletto, T., Lunardi, C.N., Lunardi, L.O., *Characterization of PLGA microparticles as a drug carrier for 3-ethoxycarbonyl-2h-benzofuro[3,2-f]-1-benzopyran-2-one. Ultrastructural study of cellular uptake and intracellular distribution*. Drug Deliv, 2006. **13**: p. 447-54.
33. Ravi Kumar, M.N.V., Bakowsky, U., Lehr, C.M., *Preparation and characterization of cationic PLGA nanospheres as DNA carriers*. Biomaterials, 2004. **25**: p. 1771-1777.
34. Soppimath, K.S., Aminabhavi, T. M., Kulkarni, A. R., Rudzinski, W. E., *Biodegradable polymeric nanoparticles as drug delivery devices*. J Control Release, 2001. **70**: p. 1-20.
35. Kumari, A., Yadav, S.K., Yadav, S.C., *Biodegradable polymeric nanoparticles based drug delivery systems*. Colloid Surface B, 2010. **75**: p. 1-18.

References

36. Mohanraj, V.J., Chen, Y., *Nanoparticles - A review*. Trop J Pharm Res, 2006. **5**: p. 561-573.
37. Look, M., Bandyopadhyay, A., Blum, J.S., Fahmy, T.M., *Application of nanotechnologies for improved immune response against infectious diseases in the developing world*. Adv Drug Deliv Rev, 2009. **62**: p. 378-393.
38. Constantinides, P.P., Chaubal, M.V., Shorr, R., *Advances in lipid nanodispersions for parenteral drug delivery and targeting*. Adv Drug Deliv Rev, 2008. **60**: p. 757-767.
39. Cheng, J., Teply, B.A., Sherifi, I., Sung, J., Luther, G., Gu, F.X., Levy-Nissenbaum, E., Radovic-Moreno, A.F., Langer, R., Farokhzad, O.C., *Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery*. Biomaterials, 2007. **28**: p. 869-876.
40. Montet, X., Weissleder, R., Josephson, L., *Imaging pancreatic cancer with a peptide-nanoparticle conjugate targeted to normal pancreas*. Bioconjugate Chem, 2006. **17**: p. 905-911.
41. Shamsipour, F., Zarnani, A.H., Ghods, R., Chamankhah, M., Forouzesh, F., Vafaei, S., Bayat, A.A., Akhondi, M.M., Oghabian, M.A., Jeddi-Tehrani, M., *Conjugation of monoclonal antibodies to super paramagnetic iron oxide nanoparticles for detection of her2/neu antigen on breast cancer cell lines*. Avicenna J Med Biotech, 2009. **1**(1): p. 27-31.
42. Leroux, J., Allemann, E., De Jaeghere, F., Doelker, E. Gurny, R., *Biodegradable nanoparticles from sustained release formulations to improved site specific drug delivery*. J Control Release, 1996. **39**: p. 339-350.
43. Owens, D.E., Peppas, N.A., *Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles*. Int J Pharm, 2006. **307**: p. 93-102.
44. Shenoy, D.B., Amiji, M.M., *Poly(ethylene oxide)-modified poly(ε-caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer*. Int J Pharm, 2005. **293**: p. 261-270.
45. Gulyaev, A.E., Gelperina, S.E., Skidam, I.N., Antropov, S., Kivman, G.Y., Kreuter, J., *Significant transport of doxorubicin into the brain with polysorbate 80 - coated nanoparticles*. Pharm Res, 1999. **16**: p. 1564-1569.
46. Nayar, R., Fidler, I.J., *The systemic activation of macrophages by liposomes containing immunomodulators*. Springer Semin Immunopathol, 1985. **8**: p. 412-428.
47. Raz, A., Bucana, C., Fogler, W.E., Poste, G., Fidler, I., *Biochemical, morphological, and ultrastructural studies on the uptake of liposomes by murine macrophages*. Cancer res, 1981. **41**: p. 487-494.
48. Tomalia, D.A., *Birth of a new macromolecular architecture: dendrimers as quantized building blocks for nanoscale synthetic polymer chemistry*. Prog Polym Sci, 2005. **30**: p. 294-324.
49. Jain, C.P., Vyas, S.P., Dixit, V.K., *Niosomal system for delivery of rifampicin to lymphatics*. Indian J Pharm Sci 2006. **68**: p. 575-578.
50. Pandey, R., Khuller, G.K., *Solid lipid particle based inhalable sustained drug delivery system against experimental tuberculosis*. Tuberculosis, 2005. **85**: p. 227-234.
51. Panyam, J., Labhasetwar, V., *Biodegradable nanoparticles for drug and gene delivery to cells and tissue*. Adv Drug Deliv Rev, 2003. **55**: p. 329-47.
52. Sahoo, S.K., Labhasetwar, V., *Nanotech approaches to drug delivery and imaging*. Drug Discov Today, 2003. **8**: p. 1112-1120.

References

53. Artursson, P., Lindmark, T., Davis, S.S., Illum, L., *Effect of chitosan on the permeability of monolayers of intestinal epithelial cells*. *Pharm Res*, 1994. **11**: p. 1358-1361.
54. Tsung, M.J., Burgess, D. J., *Preparation and characterization of gelatin surface modified PLGA microspheres*. *AAPS Pharm Sci*, 2001. **3**: p. E11.
55. Jain, R.A., *The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices*. *Biomaterials*, 2000. **21**: p. 2475-90.
56. Derakhshandeh, K., Erfan, M., Dadashzadeh, S., *Encapsulation of 9-nitrocamptothecin, a novel anticancer drug, in biodegradable nanoparticles: Factorial design, characterization and release kinetics*. *Eur J Pharm Biopharm*, 2007. **66**: p. 34-41.
57. Sahoo, S.K., Panyam, J., Prabha, S., Labhasetwar, V., *Residual polyvinyl alcohol associated with poly (D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake*. *J Control Release*, 2002. **82**: p. 105-114.
58. Tracy, M.A., Ward, K.L., Firouzabadian, L., Wang, Y., Dong, N., Qian, R., Zhang, Y., *Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheres in vivo and in vitro*. *Biomaterials*, 1999. **20**: p. 1057-1062.
59. Labhasetwar, V., Song, C., Humphrey, W., Shebuski, R., Levy, R. J., *Arterial uptake of biodegradable nanoparticles: effect of surface modifications*. *J Pharm Sci*, 1998. **87**: p. 1229-34.
60. Song, C.X., Labhasetwar, V., Murphy, H., Qu, X., Humphrey, W.R., Shebuski, R.J., Levy, R.J., *Formulation and characterization of biodegradable nanoparticles for intravascular local drug delivery*. *J Control Release*, 1997. **43**: p. 197-212.
61. Thapa, P., Zhang, G., Xia, C., Gelbard, A., Overwijk, W.W., Liu, C., Hwu, P., Chang, D.Z., Courtney, A., Sastry, J.K., Wang, P.G., Li, C., Zhou, D., *Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergy*. *Vaccine*, 2009. **27**: p. 3484-3488.
62. Arias-Negrete, S., Keller, K., Chadee, K., *Proinflammatory cytokines regulate cyclooxygenase-2 mRNA expression in human macrophages*. *Biochem Biophys Res Commun*, 1995. **208**: p. 582-9.
63. Fonseca, C., Simoes, S., Gaspar, R., *Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity*. *J Control Release*, 2002. **83**: p. 273-286.
64. Di Toro, R., Betti, V., Spampinato, S., *Biocompatibility and integrin-mediated adhesion of human osteoblasts to poly(DL-lactide-co-glycolide) copolymers*. *Eur J Pharm Sci*, 2004. **21**: p. 161-169.
65. Damgé, C., Maincent, P., Ubrich, N., *Oral delivery of insulin associated to polymeric nanoparticles in diabetic rats*. *J Control Release*, 2007. **117**: p. 163-170.
66. Sarmiento, B., Ribeiro, A., Veiga, F., Sampaio, P., Neufeld, R., Ferreira, D., *Alginate/Chitosan Nanoparticles are Effective for Oral Insulin Delivery*. *Pharm Res*, 2007. **24**: p. 2198-2206.
67. Silva, M., Ferreira, E.I., Leite, C.Q.F., Sato, D.N., *Preparation of Polymeric Micelles for Use as Carriers of Tuberculostatic Drugs*. *Trp J Pharm Res*, 2007. **6**: p. 815-824.
68. Azarmi, S., Roa, W.H., Löbenberg, R., *Targeted delivery of nanoparticles for the treatment of lung diseases*. *Adv Drug Deliv Rev*, 2008. **60**: p. 863-875.

References

69. Ohashi, K., Kabasawa, T., Ozeki, T., Okada, H., *One-step preparation of rifampicin/poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis*. J Control Release, 2009. **135**: p. 19-24.
70. Kumar, P.V., Asthana, A., Dutta, T., Jain, N.K., *Intracellular macrophage uptake of rifampicin loaded mannosylated dendrimers*. J Drug Target, 2006. **14**: p. 546-556.
71. Peters, K., Leitzke, S., Diederichs, J.E., Borner, K., Hahn, H., Muller, R.H., Ehlers, S., *Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection*. J Antimicrob Chemother, 2000. **45**: p. 77-83.
72. Oh, Y., Nix, D.E., Straubinger, R.M., *Formulation and efficacy of liposome-encapsulated antibiotics for therapy of intracellular Mycobacterium avium infection*. Antimicrob Agents Chemother, 1995. **39**: p. 2104-2111.
73. Russell, D.G., Cardona, P., Kim, M., Allain, S., Altare, F., *Foamy macrophages and the progression of the human tuberculosis granuloma*. Nat Immunol, 2009. **10**: p. 943-948.
74. Ernst, J.D., *Macrophage receptors for Mycobacterium tuberculosis*. Infect Immun, 1998. **66**: p. 1277-1281.
75. Zimmerli, S., Edwards, S., Ernst, J.D., *Selective receptor blockade during phagocytosis does not alter the survival and growth of Mycobacterium tuberculosis in human macrophages*. Am J Respir Cell Mol Biol, 1996. **15**: p. 760-770.
76. Yamaguchi, Y., Kunitomo, M., Haginaka, J., *Assay methods of modified lipoproteins in plasma*. J Chromatogr B 2002. **781**: p. 313-330.
77. Suzuki, H., Kurihara, Y., Takeya, M., Kamada, N., Kataoka, M., Jishage, K., Ueda, O., Sakaguchi, H., Higashi, T., Suzuki, T., Takashima, Y., Kawabe, Y., Cynshi, O., Wada, Y., Honda, M., Kurihara, H., Aburatani, H., Doi, T., Matsumoto, A., Azuma, S., Noda, T., Toyoda, Y., Itakura, H., Yazaki, Y., Horiuchi, S., Takahashi, K., Kruijt, J.K., van Berkel, T.J.C., Steinbreger, U.P., Ishibashi, S., Maeda, N., Gordon, S., Kodama, T., *A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection*. Nature, 1997. **386**: p. 292-296.
78. Majumdar, S., Basu, S.K., *Killing of intracellular Mycobacterium tuberculosis by receptor-mediated drug delivery*. Antimicrob Agents Chemother, 1991. **35**: p. 135-140.
79. Chono, S., Tanino, T., Seki, T., Morimoto, K., *Efficient drug targeting to rat alveolar macrophages by pulmonary administration of ciprofloxacin incorporated into mannosylated liposomes for treatment of respiratory intracellular parasitic infections*. J Control Release, 2008. **127**: p. 50-58.
80. Av-Gay, Y., Sobouti, R., *Cholesterol is accumulated by mycobacteria but its degradation is limited to non-pathogenic fast-growing mycobacteria*. Can J Microbiol, 2000. **46**: p. 826-831.
81. Gatfield, J., Pieters, J., *Essential role for cholesterol in entry of mycobacteria into macrophages*. Science, 2000. **288**: p. 1647-1650.
82. Peyron, P., Vaubourgeix, J., Poquet, Y., Levillain, F., Botanch, C., Bardou, F., Daffe, M., Emile, J., Marchou, B., Cardona, P., de Chastellier, C., Altare, F., *Foamy macrophages from tuberculous patients granulomas constitute a nutrient-rich reservoir for M.tuberculosis persistence*. PLOS Pathogens, 2008. **4**: p. e1000204.

References

83. Astarie-Dequeker, C., Le Guyader, L., Malaga, W., Seaphanh, F., Chalut, C., Lopez, A., Guilhot, C., *Phthiocerol Dimycocerosates of M. tuberculosis participate in macrophage invasion by inducing changes in the organization of plasma membrane lipids*. PLOS Pathogens, 2009. **5**: p. e1000289.
84. Kurup, I.G., Mahadevan, P.R., *Cholesterol metabolism of macrophages in relation to the presence of Mycobacterium leprae*. J Biosci, 1982. **4**: p. 307–316.
85. Caceres, N., Tapia, G., Ojanguren, I., Altare, F., Gil, O., Pinto, S., Vilaplana, C., Cardona, P., *Evolution of foamy macrophages in the pulmonary granulomas of experimental tuberculosis models*. Tuberculosis, 2009. **89**: p. 175-182.
86. Peyron, P., Bordier, C., N'Diaye, E., Maridonneau-Parini, I., *Nonopsonic phagocytosis of mycobacterium kansasii by human neutrophils depends on cholesterol and is mediated by CR3 associated with glycosylphosphatidylinositol-anchored proteins*. J Immunol, 2000. **165**: p. 5186–5191.
87. Russell, D.G., Mwandumba, H.C., Rhoades, E.E., *Mycobacterium and the coat of many lipids*. J Cell Biol, 2002. **158**: p. 421–426.
88. Ferrari, G., Langen, H., Naito, M., Pieters, J., *A coat protein on phagosomes involved in the intracellular survival of mycobacteria*. Cell, 1999. **97**: p. 435-447.
89. Pieters, J., Gatfield, J., *Hijacking the host: survival of pathogenic mycobacteria inside macrophages*. Trends Microbiol, 2002. **10**: p. 142-146.
90. Jayachandran, R., Sundaramurthy, V., Combaluzier, B., Mueller, P., Korf, H., Huygen, K., Miyazaki, T., Albrecht, I., Massner, J., Pieters, J., *Survival of mycobacteria in macrophages is mediated by coronin 1-dependent activation of calcineurin*. Cell, 2007. **130**: p. 37–50.
91. Pieters, J., *Evasion of host cell defense mechanisms by pathogenic bacteria*. Curr Opin Immunol, 2001. **13**: p. 37-44.
92. Kaul, D., Anand, P.K., Verma, I., *Cholesterol-sensor initiates M. tuberculosis entry into human macrophages*. Mol Cell Biochem, 2004. **258**: p. 219–222.
93. Kaul, D., *Coronin-1A epigenomics governs mycobacterial persistence in tuberculosis*. FEMS Microbiol Lett, 2008. **278**: p. 10-14.
94. De Chastellier, C., Lang, T., Thilo, L., *Phagocytic processing of the macrophage endoparasite, Mycobacterium avium, in comparison to phagosomes which contain Bacillus subtilis or latex beads*. Eur J Cell Biol, 1995. **68**: p. 167-182.
95. De Chastellier, C., Thilo, L., *Phagosome maturation and fusion with lysosomes in relation to surface property and size of the phagocytic particle*. Eur J Cell Biol, 1997. **74**: p. 49-62.
96. De Chastellier, C., Thilo, L., *Cholesterol depletion in Mycobacterium avium - infected macrophages overcome the block in phagosome maturation and leads to the reversible sequestration of viable mycobacteria in phagolysosome derived autophagic vacuoles*. Cell Microbiol, 2006. **8**: p. 242-256.
97. Sekanka, G., Baird, M., Minnikin, D., Grooten, J., *Mycolic acids for the control of tuberculosis*. Expert Opin Ther Patents, 2007. **17**: p. 315-331.
98. Berg, S., Kaur, D., Jackson, M., Brennan, P.J., *The glycosyltransferases of Mycobacterium tuberculosis—roles in the synthesis of arabinogalactan, lipoarabinomannan, and other glycoconjugates*. Glycobiology, 2007. **17**: p. 35R–56R.

References

99. Minnikin, D.E., Kremer, L., Dover, L.G., Besra, *The methyl-branched fortifications of Mycobacterium tuberculosis*. Chem Biol, 2002. **9**: p. 545-553.
100. Lambert, P.A., *Cellular impermeability and uptake of biocides and antibiotics in Gram-positive bacteria and mycobacteria*. J Appl Microbiol, 2002. **92**(Suppl): p. 46S-54S.
101. Minnikin, D.E., Minnikin, S.M., Parlett, J.H., Goodfellow, M., Magnusson, M., *Mycolic acid patterns of some species of Mycobacterium*. Arch Microbiol, 1984. **139**: p. 225-231.
102. Villeneuve, M., Kawai, M., Kanashima, H., Watanabe, M., Minnikin, D.E., Nakahara, H., *Temperature dependence of the Langmuir monolayer packing of mycolic acids from Mycobacterium tuberculosis*. Biochim Biophys Acta, 2005. **1715**: p. 71-80.
103. Villeneuve, M., Kawai, M., Watanabe, M., Aoyagi, Y., Hitotsuyanagi, Y., Takeya, K., Gouda, H., Hirono, S., Minnikin, D.E., Nakahara, H., *Conformational behavior of oxygenated mycobacterial mycolic acids from Mycobacterium bovis BCG*. Biochim Biophys Acta, 2007. **1768** p. 1717–1726.
104. Takayama, K., Wang, C., Besra, G.S., *Pathway to synthesis and processing of mycolic acids in Mycobacterium tuberculosis*. Clin Microbiol Rev, 2005. **18**: p. 81-101.
105. Barry 3rd, C.E., Lee, R.E., Mdluli, K., Sampson, A.E., Schroeder, B.G., Slayden, R.A., Yuan, Y. *Mycolic acids: structure, biosynthesis and physiological functions*. Prog Lipid Res, 1998. **37**: p. 143-179.
106. Asselineau, C., Asselineau, J., Laneelle, G., Laneelle, M.A., *The biosynthesis of mycolic acids by mycobacteria: current and alternative hypotheses*. Prog Lipid Res, 2002. **41**: p. 501-523.
107. Belisle, J.T., Vissa, V.D., Sievert, T., Takayama, K., Brennan, P.J., Besra, G.S., *Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis*. Science, 1997. **276**: p. 1420-1422.
108. Dubnau, E., Chan, J., Raynaud, C., Mohan, V. P., Laneelle, M.A., Yu, K., Quemard, A., Smith, I., Daffe, M., *Oxygenated mycolic acids are necessary for virulence of Mycobacterium tuberculosis in mice*. Mol Microbiol, 2000. **36**: p. 630-637.
109. Fujita, Y., Okamoto, Y., Uenishib, Y., Sunagawab, M., Uchiyamac, T., Yano, I., *Molecular and supra-molecular structure related differences in toxicity and granulomatogenic activity of mycobacterial cord factor in mice*. Microb Pathog, 2007. **43**: p. 10-21.
110. Liu, J., Barry 3rd, C.E., Besra, G.S., Nikaido, H., *Mycolic acid structure determines the fluidity of the mycobacterial cell wall*. J Biol Chem, 1996. **271**: p. 29545-29551.
111. Lyashchenko, K., Colangeli, R., Houde, M., Al Jahdali, H., Menzies, D., Gennaro, M.L., *Heterogeneous antibody responses in tuberculosis*. Infect Immun, 1998. **66**: p. 3936–3940.
112. Fujiwara, N., Pan, J., Enomoto, K., Terano, Y., Honda, T., Yano, I., *Production and partial characterization of anti-cord factor (trehalose-6,6P-dimycolate) IgG antibody in rabbits recognizing mycolic acid subclasses of Mycobacterium tuberculosis or Mycobacterium avium*. FEMS Immunol Med Microbiol, 1999. **24**: p. 141-149.
113. Fujita, Y., Naka, T., McNeil, M.R., Yano, I., *Intact molecular characterization of cord factor (trehalose 6,69-dimycolate) from nine species*

References

- of mycobacteria by MALDI-TOF mass spectrometry. *Microbiology*, 2005. **151**: p. 3403–3416.
114. Shui, G., Bendt, A.K., Pethe, K., Dick, T., Wenk, M.R., *Sensitive profiling of chemically diverse bioactive lipids*. *J Lipid Res*, 2007. **48**: p. 1976–1984.
115. Yuan, Y., Crane, D.C., Musser, J.M., Sreevatsan, S., Barry 3rd, C.E., *MMA5-1, the branch point between cis- and trans-cyclopropane containing oxygenated mycolates in Mycobacterium tuberculosis*. *J Biol Chem*, 1997. **272**: p. 10041–10049.
116. Beckman, E.V., Porcelli, S.A., Morita, C.T., Behar, S.M., Furlong, S.T., Brenner, M.B., *Recognition of a lipid antigen by CD1-restricted $\alpha\beta^+$ T cells*. *Nature*, 1994. **372**: p. 691 – 694.
117. Lemmer, Y., Thanyani, S.T., Vrey, P.J., Driver, C.H.S., Venter, L., van Wyngaardt, S., ten Bokum, A.M.C., Ozoemena, K.I., Pilcher, L.A., Fernig, D.G., Stoltz, A.C., Swai, H.S., Verschoor, J.A., *Detection of Antimycolic Acid Antibodies by Liposomal Biosensors*. *Methods Enzymol*, 2009. **464**: p. 80-102.
118. Schleicher, G.K., Feldman, C., Vermaak, Y., Verschoor, J.A., *Prevalence of anti-mycolic acid antibodies in patients with pulmonary tuberculosis co-infected with HIV*. *Clin Chem Lab Med*, 2002. **40**: p. 882-887.
119. Pan, J., Fujiwara, N., Oka, S., Maekura, R., Ogura, T., and Yano, L., *Anti-Cord Factor (Trehalose 6,6'-Dimycolate) IgG antibody in tuberculosis patients recognizes mycolic acid subclasses*. *Microbiol Immunol*, 1999. **43**: p. 863 – 869.
120. Thanyani, S.T., Roberts, V., Siko, D.G., Vrey, P., Verschoor, J.A., *A novel application of affinity biosensor technology to detect antibodies to mycolic acid in tuberculosis patients*. *J Immunol Methods*, 2008. **332**: p. 61-72.
121. Benadie, Y., Deysel, M., Siko, D. G., Roberts, V. V., Van Wyngaardt, S., Thanyani, S. T., Sekanka, G., Ten Bokum, A. M., Collett, L. A., Grooten, J., Baird, M. S., Verschoor, J. A., *Cholesteroid nature of free mycolic acids from M. tuberculosis*. *Chem Phys Lipids*, 2008. **152**: p. 95-103.
122. Indrigo, J., Hunter, R.L., Actor, J.K., *Influence of trehalose 6,6H-dimycolate (TDM) during mycobacterial infection of bone marrow macrophages*. *Microbiology*, 2002. **148**: p. 1991–1998.
123. Indrigo, J., Hunter, R.L., Actor, J.K., *Cord factor trehalose 6,69-dimycolate (TDM) mediates trafficking events during mycobacterial infection of murine macrophages*. *Microbiology* 2003. **149**: p. 2049–2059.
124. Lima, V.M.F., Bonato, V.L.D., Lima, K.M., Dos Santos, S.A., Dos Santos, R.R., Goncalves, E.D.C., Faccioli, L.H., Branda, I.T., Rodrigues, J.M., Silva, C.L., *Role of trehalose dimycolate in recruitment of cells and modulation of production of cytokines and NO in tuberculosis*. *Infect Immun*, 2001. **69**: p. 5305–5312.
125. Pandey, A.K., Sasseti, C.M., *Mycobacterial persistence requires the utilization of host cholesterol*. *P Natl Acad Sci USA*, 2008. **105**: p. 4376–4380.
126. Korf, J.E., Pynaert, G., Tournoy, K., Boonefaes, T., van Oosterhout, A., Ginneberge, D., Haegeman, A., Verschoor, J.A., De Baetseller, P., Grooten, J., *Macrophage reprogramming by mycolic acids promotes a tolerogenic response in experimental asthma*. *Am J Resp Crit Care*, 2006. **174**: p. 152 - 160.
127. Korf, H., Van der Beken, S., Romano, M., Steffensen, K.R., Stijlemans, B., Gustafsson, J., Grooten, J., Huygen, K., *Liver X receptors contribute to the*

References

- protective immune response against Mycobacterium tuberculosis in mice.* J Clin Invest 2009. **119**: p. 1626-1637.
128. Means, T.K., Lien, E., Yoshimura, A., Wang, S., Golenbock, D.T., Fenton, M.J., *The CD14 ligands of lipoarabinomannan and lipopolysaccharide differ in their requirement for Toll-like receptors.* J Immunol 1999. **163**: p. 6748-6755.
129. Means, T.K., Wang, S., Lien, E., Yoshimura, A., Golenbock, D.T., Fenton, M.J., *Human toll-like receptors mediate cellular activation by Mycobacterium tuberculosis.* J Immunol 1999. **163**: p. 3920-3927.
130. Bowdish, D.M.E., Sakamoto, K., Kim, M., Kroos, M., Mukhopadhyay, S., Leifer, C.A., Tryggvason, K., Gordon, S., Russell, D.G., *MARCO, TLR2, and CD14 are required for macrophage cytokine responses to mycobacterial trehalose dimycolate and Mycobacterium tuberculosis.* PLOS Pathogens, 2009. **5**: p. e1000474.
131. Tailleux, L., Neyrolles, O., Honore´-Bouakline, S., Perret, E., Sanchez, F., Abastado, J., Lagrange, P.H., Gluckman, J., Rosenzweig, M., Herrmann, J., *Constrained intracellular survival of Mycobacterium tuberculosis in human dendritic cells.* J Immunol, 2003. **170**: p. 1939–1948.
132. Armstrong, J.A., D'arcy Hart, P., *Phagosome-lysosome interactions in cultured macrophages infected with virulent tubercle bacilli.* J Exp Med, 1975. **142**: p. 1-15.
133. Vergne, I., Fratti, R.A., Hill, P.J., Chua, J., Belisle, J., Deretic, V., *Mycobacterium tuberculosis phagosome maturation arrest: Mycobacterial phosphatidylinositol analog phosphatidylinositol mannoside stimulates early endosomal fusion.* Mol Biol Cell, 2004. **15**: p. 751-760.
134. Axelrod, S., Oschkinat, H., Enders, J., Schlegel, B., Brinkmann, V., Kaufmann, S.H.E., Haas, H. Schaible, U.E., *Delay of phagosome maturation by a mycobacterial lipid is reversed by nitric oxide.* Cell Microbiol, 2008. **10**: p. 1530–1545.
135. Hmama, Z., Sendide, K., Talal, A., Garcia, R., Dobos, K., Reiner, N.E., *Quantitative analysis of phagolysosome fusion in intact cells: inhibition by mycobacterial lipoarabinomannan and rescue by an 1a,25-dihydroxyvitamin D3–phosphoinositide 3-kinase pathway.* J Cell Sci, 2004. **117**: p. 2131-2139.
136. Appelmelk, B.J., den Dunnen, J., Driessen, N.N., Ummels, R., Pak, M., Nigou, J., Larrouy-Maumus, G., Gurcha, S.S., Movahedzadeh, F., Geurtsen, J., Brown, E.J., Eysink Smeets, M.M., Besra, G.S., Willemsen, P.T.J., Lowary, T.L., van Kooyk, Y., Maaskant, J.J., Stoker, N.G., van der Ley, P., Puzo, G., Vandenbroucke-Grauls, C.M.J.E., Wieland, C.W., van der Poll, T., Geijtenbeek, T.B.H., van der Sar, A.M., Bitter, W., *The mannose cap of mycobacterial lipoarabinomannan does not dominate the Mycobacterium–host interaction.* Cell Microbiol, 2008. **10**: p. 930–944.
137. Beatty, W.L., Rhoades, E.R., Ullrich, H.J., Chatterjee, D., Heuser, J.E., Russell, D.G., *Trafficking and release of Mycobacterial lipids from infected macrophages* Traffic, 2000. **1**: p. 235 - 247.
138. Beatty, W.L., Ullrich, H-J., Russell, D.G., *Mycobacterial surface moieties are released from infected macrophages by a constitutive exocytic event.* Eur J Cell Biol, 2001. **80**: p. 31-40.
139. Pietersen, R., Thilo, L., de Chastellier, C., *Mycobacterium tuberculosis and Mycobacterium avium modify the composition of the phagosomal membrane*

References

- in infected macrophages by selective depletion of cell surface derived glycoconjugates.* Eur J Cell Biol, 2004. **83**: p. 153-158.
140. De Chastellier, C., *The many niches and strategies used by pathogenic mycobacteria for survival within host macrophages.* Immunobiol, 2009. **214**: p. 526–542.
 141. Ojha, A.K., Baughn, A.D., Sambandan, D., Hsu, T., Trivelli, X., Guerardel, Y., Alahari, A., Kremer, L., Jacobs Jr, W.R., Hatfull, G.F., *Growth of Mycobacterium tuberculosis biofilms containing free mycolic acids and harbouring drug-tolerant bacteria.* Mol Microbiol, 2008. **69**: p. 164–174.
 142. Ojha, A.J., Trivelli, X., Guerardel, Y., Kremer, L., Hatfull, G.F., *Enzymatic hydrolysis of trehalose dimycolate releases free mycolic acids during mycobacterial growth in biofilms.* J Biol Chem, 2010: p. doi/10.1074/jbc.M110.112813.
 143. Cardona, P.J., Llatjos, R., Gordillo, S., Diaz, J., Ojanguren, I., Ariza, A., Ausina, V., *Evolution of Granulomas in Lungs of Mice Infected Aerogenically with Mycobacterium tuberculosis.* Scand J Immunol, 2000. **52**: p. 156-163.
 144. Kondo, E., Kanai, K., *Accumulation of cholesterol esters in macrophages incubated with mycobacteria in vitro.* Jpn J Med Sci Biol, 1976 (b). **29**: p. 123-137.
 145. Cardona, P.J., Gordillo, S., Diaz, J., Tapia, G., Amat, I., Pallares, A., Vilaplana, C., Ariza, A., Ausina, V., *Widespread bronchogenic dissemination makes DBA/2 mice more susceptible than C57BL/6 mice to experimental aerosol infection with Mycobacterium tuberculosis.* Infect Immun, 2003. **71**: p. 5845-5854.
 146. Saunders, B.M., Cooper, A.M., *Restraining mycobacteria: Role of granulomas in mycobacterial infections.* Immunol Cell Biol, 2000. **78**: p. 334–341.
 147. Lamb, D.C., Kelly, D. E., Manning, N. J., Kelly, S. L., *A sterol biosynthetic pathway in Mycobacterium.* FEBS Lett, 1998. **437**: p. 142-144.
 148. Brzostek, A., Pawelczyk, J., Rumijowska-Galewicz, A., Dziadek, B., Dziadek, J., *Mycobacterium tuberculosis is able to accumulate and utilize cholesterol.* J Bacteriol, 2009. **191**: p. 6584–6591.
 149. Cole, S.T., Brosch, R., Parkhill, J., Garnier, T., Churcher, C., Harris, D., Gordon, S.V., Eiglmeier, K., Gas, S., Barry 3rd, C.E., Tekaia, F., Badcock, K., Basham, D., Brown, D., Chillingworth, T., Connor, R., Davies, R., Devlin, K., Feltwell, T., Gentles, S., Hamlin, N., Holroyd, S., Hornsby, T., Jagels, K., Barrell, B.G., *Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence.* Nature, 1998. **393**: p. 537-544.
 150. Joshi, S.M., Pandey, A.K., Capite, N., Fortune, S.M., Rubin, E.J., Sasseti, C.M., *Characterization of mycobacterial virulence genes through genetic interaction mapping.* PNAS, 2006. **103**: p. 11760–11765.
 151. Brzostek, A., Dziadek, B., Rumijowska-Galewicz, A., Pawelczyk, J., Dziadek, J., *Cholesterol oxidase is required for virulence of Mycobacterium tuberculosis.* FEMS Microbiol Lett, 2007. **275**: p. 106–112.
 152. Rengarajan, J., Bloom, B.R., Rubin, E.J., *Genome-wide requirements for Mycobacterium tuberculosis adaptation and survival in macrophages.* P Natl Acad Sci USA, 2005. **102**: p. 8327–8332.
 153. Chang, J.C., Harik, N.S., Liao, R.P., Sherman, D.R., *Identification of Mycobacterial Genes That Alter Growth and Pathology in Macrophages and in Mice.* J Infect Dis, 2007. **196**: p. 788-795.

References

154. Miner, M.D., Chang, J.C., Pandey, A.K., Sassetti, C.M., Sherman, D.R., *Role of cholesterol in Mycobacterium tuberculosis infection*. Indian J Exp Biol, 2009. **47**: p. 407-411.
155. Van der Geize, R., Yam, K., Heuser, T., Wilbrink, M.H., Hara, H., Anderton, M.C., Sim, E., Dijkhuizen, L., Davies, J.E., Mohn, W.W., Eltis, L.D., *A gene cluster encoding cholesterol catabolism in a soil actinomycete provides insight into Mycobacterium tuberculosis survival in macrophages*. P Natl Acad Sci USA, 2007. **104**: p. 1947–1952.
156. Maldonado-Garcia, G., Chico-Ortiz, M., Lopez-Mariny, L.M., Sanchez-Garcia, F.J., *High-polarity Mycobacterium avium-derived lipids interact with murine macrophage lipid rafts*. Scand J Immunol, 2004. **60**: p. 463–470.
157. Hayakawa, E., Tokumasu, F., Nardone, G.A., Jin, A.J., Hackley, V.A., Dvorak, J.A., *A Mycobacterium tuberculosis-derived lipid inhibits membrane fusion by modulating lipid membrane domains*. Biophys J, 2007. **93**: p. 4018–4030.
158. Lee, J.W., Sim, S.J., Cho, S.M., Lee, J., *Characterization of a self-assembled monolayer of thiol on a gold surface and the fabrication of a biosensor chip based on surface plasmon resonance for detecting anti-GAD antibody*. Biosens Bioelectron, 2005. **20**: p. 1422–1427.
159. Mukherjee, P.S. and H.T. Karnes, *Ultraviolet and fluorescence derivatization reagents for carboxylic acids suitable for high performance liquid chromatography: a review*. Biomed Chromatogr, 1996. **10**: p. 193-204.
160. Roberts, V.V., *Immunochemical analysis of Mycolic acid antigens in Tuberculosis*. MSc Dissertation, in Department of Biochemistry, Faculty of Natural and Agricultural Sciences. 2008, University of Pretoria: Pretoria.
161. Butler, W.R., Kilburn, J. O., *High-performance liquid chromatography patterns of mycolic acids as criteria for identification of Mycobacterium chelonae, Mycobacterium fortuitum, and Mycobacterium smegmatis*. J Clin Microbiol, 1990. **28**: p. 2094-8.
162. Baginski, M., Resat, H., Borowski, E., *Comparative molecular dynamics simulations of amphotericin B-cholesterol/ergosterol membrane channels*. Biochim Biophys Acta, 2002. **1567**: p. 63-78.
163. Yuan, y., Barry III, C.E., *A common mechanism for the biosynthesis of methoxy and cyclopropyl mycolic acids in Mycobacterium tuberculosis*. P Natl Acad Sci USA, 1996. **93**: p. 12828–12833.
164. Hervé, M., Debouzy, J.C., Borowski, E., Cybulska, B., Gary-Bobo, C.M., *The role of the carboxyl and amino groups of polyene macrolides in their interactions with sterols and their selective toxicity. A ³¹P-NMR study*. Biochim Biophys Acta, 1989. **980**: p. 261-272.
165. Matsumori, N., Umegawa, Y., Oishi, T., Murata, M., *Bioactive fluorinated derivative of amphotericin B*. Bioorg Med Chem Lett, 2005. **15**: p. 3565–3567.
166. Biro, A., Cervenak, L., Balogh, A., Lorincz, A., Uray, K., Horvath, A., Romics, L., Matko, J., Fust, G., Laszlo, G., *Novel anti-cholesterol monoclonal immunoglobulin G antibodies as probes and potential modulators of membrane raft-dependent immune functions*. J Lipid Res, 2007. **48**: p. 19-29.
167. Swartz, G.M., Gentry, M.K., Amendeo, L.M., Blanchette-Mackie, E.J., Alving, C.R., *Antibodies to cholesterol*. P Natl Acad Sci USA, 1988. **85**: p. 1902-1906.
168. Siko, D.G.R., *Mycobacterial mycolic acids as immunoregulatory lipid antigens in the resistance to tuberculosis*. PhD thesis, in Department of

References

- Biochemistry. Faculty of Natural and Agricultural Sciences* 2002, University of Pretoria: Pretoria.
169. Fielding, C.J., Fielding, P.E., *Cellular cholesterol efflux*. *Biochim Biophys Acta*, 2001. **1533**: p. 175-189.
 170. Kruth, H.S., Ifrim, I., Chang, J., Addadi, L., Perl-Treves, D., Zhang, W., *Monoclonal antibody detection of plasma membrane cholesterol microdomains responsive to cholesterol trafficking*. *J Lipid Res*, 2001. **42**: p. 1492–1500.
 171. Bogunia-Kubik, K., Sugisaka, M., *From molecular biology to nanotechnology and nanomedicine*. *Biosystems*, 2002. **65**: p. 123-38.
 172. Kisich, K.O., Gelperina, S., Higgins, M.P., Wilson, S., Shipulo, E., Oganesyanyan, E., Heifets, L., *Encapsulation of moxifloxacin within poly(butyl cyanoacrylate) nanoparticles enhances efficacy against intracellular Mycobacterium tuberculosis*. *Int J Pharm*, 2007. **345**: p. 154–162.
 173. Torchilin, V.P., *Structure and design of polymeric surfactant-based drug delivery systems*. *J Control Release*, 2001. **73**: p. 137–172.
 174. Lamprecht, A., Ubrich, N., Hombreiro Perez, M., Lehr, C-M., Hoffman, M., Maincent, P., *Biodegradable monodispersed nanoparticles prepared by pressure homogenization-emulsification*. *Int J Pharm*, 1999. **184**: p. 97-105.
 175. Brunner, T.J., Wick, P., Manser, P., Spohn, P., Grass, R.N., Limbach, L.K., Brunnink, A., Stark, W.J., *In vitro cytotoxicity of oxide nanoparticles: comparison to asbestos, silica, and the effect of particle solubility*. *Environ Sci Technol*, 2006. **40**: p. 4374-4381.
 176. Choi, J.Y., Lee, S.H., Na, H.B., An, K., Hyeon, T., Seo, T.S., *In vitro cytotoxicity screening of water-dispersible metal oxide nanoparticles in human cell lines*. *Bioproc Biosyst Eng*, 2010. **33**: p. 21-30.
 177. Merget, R., Bauer, T., Küpper, H.U., Philippou, S., Bauer, H.D., Breitstadt, R., Bruening, T., *Health hazards due to the inhalation of amorphous silica*. *Arch Toxicol* 2002. **75**: p. 625-634.
 178. Sharma, V., Shukla, R.K., Saxena, N., Parmar, D., Das, M., Dhawan, A., *DNA damaging potential of zinc oxide nanoparticles in human epidermal cells*. *Toxicol Lett*, 2009. **185**: p. 211-218.
 179. Spano, A., Monaco, G., Barni, S., Sciola, L., *Expression of cell kinetics and death during monocyte-macrophage differentiation: effects of Actinomycin D and Vinblastine treatments*. *Histochem Cell Biol*, 2007. **127**: p. 79-94.
 180. Rejman, J., Oberle, V., Zuhorn, I.S., Hoekstra, D., *Size-dependent internalization of particles via the pathways of clathrin and caveolae-mediated endocytosis*. *Biochem J*, 2004. **377**: p. 159-169.
 181. Mosiman, V.L., Patterson, B.K., Canterero, L., Goolsby, C.L., *Reducing cellular autofluorescence in flow cytometry: an in situ method*. *Cytometry (Communications in Clinical Cytometry)*, 1997. **30**: p. 151-156.
 182. Al-Taei, S., Penning, N.A., Simpson, J.C., Futaki, S., Takeuchi, T., Nakase, I., Jones*, A.T., *Intracellular Traffic and Fate of Protein Transduction Domains HIV-1 TAT Peptide and Octaarginine. Implications for Their Utilization as Drug Delivery Vectors*. *Bioconjugate Chem*, 2006. **17**: p. 90-100.
 183. Tsai, C., Lin, C., Wang, T., Chou, A., Chou, M., Lee, C., Peng, I., Liao, J., Chen, Y., Pan, C., *Dynasore inhibits rapid endocytosis in bovine chromaffin cells*. *Am J Physiol-Cell Ph*, 2009. **297**: p. C397–C406.

References

184. Fukunaga, M. and K. Tsuruda, *Actinobacillus actinomycetemcomitans induces lethal effects on the macrophage-like human cell line U937*. Oral Microbiol Immunol, 2001. **16**: p. 284-9.
185. Richardson, S.C.W., Wallom, K., Ferguson, E.L., Deacon, S.P.E., Davies, M.W., Powell, A.J., Piper, R.C., Duncan, R., *The use of fluorescence microscopy to define polymer localisation to the late endocytic compartments in cells that are targets for drug delivery*. J Control Release, 2008. **127**: p. 1-11.
186. Hasegawa, T., Hirota, K., Tomoda, K., Ito, F., Inagawa, H., Kochi, C., Soma, G., Makino, K., Terada, H., *Phagocytic activity of alveolar macrophages toward polystyrene latex microspheres and PLGA microspheres loaded with anti-tuberculosis agent*. Colloid surface B, 2007. **60**: p. 221-228.
187. Butler, W.R., Guthertz, L.S., *Mycolic acid analysis by high-performance liquid chromatography for identification of Mycobacterium species*. Clin Microbiol Rev, 2001. **14**: p. 704-726.
188. Duffey, P.S., Guthertz, L.S., Evans, G.C., *Improved rapid identification of mycobacteria by combining solid-phase extraction with high-performance liquid chromatography analysis of BACTEC cultures*. J Clin Microbiol, 1996. **34**: p. 1939-43.
189. Kellogg, J.A., Bankert, D.A., Withers, G.S., Sweimler, W., Kiehn, T.E., Pfyffer, G.E., *Application of the Sherlock Mycobacteria Identification System using high-performance liquid chromatography in a clinical laboratory*. J Clin Microbiol, 2001. **39**: p. 964-70.
190. Hagen, S.R. and J.D. Thompson, *Analysis of mycolic acids by high-performance liquid chromatography and fluorimetric detection. Implications for the identification of mycobacteria in clinical samples*. J Chromatogr A, 1995. **692**: p. 167-72.
191. Khanuja, S.P.S., Srivastava, S., Kumar, T.R.S., Shasany, A.K., Darokar, M.P., Awasthi, S., *PCT WO 03/080860. A quick and sensitive method of quantifying mycolic acid*, W.I.P. Organisation, Editor. 2003.
192. Young, F.M., Phungtamdet, W., Sanderson, B.J.S., *Modification of MTT assay conditions to examine the cytotoxic effects of amitrax on the human lymphoblastoid cell line, WIL2NS*. Toxicol In Vitro, 2005. **19**: p. 1051-1059.
193. Sinha, D., Bhattacharya, D.K., Mandal, C., *A colorimetric assay to evaluate the chemotherapeutic response of children with acute lymphoblastic leukemia (ALL) employing AchatininH: a 9-O-acetyl sialic acid binding lectin*. Leuk Res, 1999. **23**: p. 803-809.
194. Kohro, T., Tanaka, T., Murakami, T., Wada, Y., Aburatani, H., Hamakubo, T., Kodama, T., *A comparison of differences in the gene expression profiles phorbol-12-myristate 13-acetate differentiated THP-1 cells and human monocyte derived macrophage*. J Atheroscler Thromb, 2004. **11**: p. 88-97.
195. Grifliths, G., Back, R., Marsh, M., *A quantitative analysis of the endocytic pathway in baby hamster kidney cells*. J Cell Biol, 1989. **109**: p. 2703-2720.
196. Green, S.A., Zimmer, K., Grifliths, G., Mellman, I., *Kinetics of intracellular transport and sorting of lysosomal membrane and plasma membrane proteins*. J Cell Biol, 1987. **105**: p. 1227-1240.
197. Semete, B., Booysen, L., Lemmer, Y., Kalombo, L., Katata, L., Verschoor, J., Swai, H.S., *In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems*. Nanomedicine, 2010. **6**(5): p. 662-671.

References

198. Sun, E.Y., Josephson, L., Kelly, K.A., Weissleder, R., *Development of Nanoparticle Libraries for Biosensing*. *Bioconjugate Chem*, 2006. **17**: p. 109-113.
199. Trombone, A.P.F., Silva, C.L., Almeida, L.P., Rosada, R.S., Lima, K.M., Oliver, C., Jamur, M.C., Coelho-Castelo, A.A.M., *Tissue distribution of DNA-Hsp65/TDM-loaded PLGA microspheres and uptake by phagocytic cells*. *Genet Vaccines Ther*, 2007. **5**: p. 9.
200. Murray, J.W., Wolkoff, A.W., *Roles of the cytoskeleton and motor proteins in endocytic sorting*. *Adv Drug Deliv Rev*, 2003. **55**: p. 1385-1403.
201. Vercauteren, D., Vandenbroucke, R.E., Jones, A.T., Rejman, J., Demeester, J., De Smedt, S.C., Sanders, N.N., Braeckmans, K., *The use of inhibitors to study endocytic pathways of gene carriers: optimization and pitfalls*. *Molecular Therapy*, 2009. **18**: p. 561-569.
202. Zahoor, A., Sharma, S., Khuller, G.K., *Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis*. *Int J Antimicrob Agents*, 2005. **26**: p. 298-303.
203. Zahoor, A., Pandey, R., Sharma, S., Khuller, G.K., *Pharmacokinetic and pharmacodynamic behaviour of antitubercular drugs encapsulated in alginate nanoparticles at two doses*. *Int J Antimicrob Agents*, 2006. **27**: p. 409-416.
204. Zahoor, A., Sharma, S., Khuller, G.K., *Chemotherapeutic evaluation of alginate nanoparticle-encapsulated azole antifungal and antitubercular drugs against murine tuberculosis*. *Nanomedicine*, 2007. **3**: p. 239-243.
205. Dutt, M., Khuller, G. K., *Liposomes and PLG microparticles as sustained release antitubercular drug carriers - an in vitro-in vivo study*. *Int J Antimicrob Agents*, 2001. **18**: p. 245-52.
206. Johnson, C.M., Pandey, R., Sharma, S., Khuller, G.K., Basaraba, R.J., Orme, I.M., Lenaerts, A.J., *Oral therapy using nanoparticle-encapsulated antituberculosis drugs in guinea pigs infected with Mycobacterium tuberculosis*. *Antimicrob Agents Chemother*, 2003. **49**: p. 4335-4338.
207. Jones, A.T., *Macropinocytosis: searching for an endocytic identity and a role in the uptake of cell penetrating peptides*. *J Cell Mol Med*, 2007. **11**: p. 670-684.
208. Sebattjane, S.I., *Anti-tuberculosis drug design based on a possible mimicry between host and pathogen lipids*. *MSc Dissertation*, in *Department of Biochemistry. Faculty of Natural and Agricultural Sciences* 2003, University of Pretoria: Pretoria.
209. Goodrum, M.A., Siko, D.G.R., Niehues, T., Eichelbauer, D., Verschoor, J.A., *Mycolic acids from Mycobacterium tuberculosis: Purification by countercurrent distribution and T cell stimulation*. *Microbios*, 2001. **106**: p. 55-67.
210. Biro, A., Horvath, A., Varga, L., Nemesanszky, E., Csepregi, A., David, K., Tolvaj, G., Ibranyi, E., Telegdy, L., Par, A., Romics, L., Karadi, I., Horanyi, M., Gervain, J., Ribiczey, P., Csondes, M., Fust, G., *Serum anti-cholesterol antibodies in chronic hepatitis-C patients during IFN- α -2b treatment*. *Immunobiol*, 2003. **207**: p. 161-168.
211. Horvath, A., Fustab, G., Horvath, I., Vallus, G., Duba, J., Harcos, P., Prohaszka, Z., Rajnavolgyi, E., Janoskuti, L., Kovacs, M., Csaszar, A., Romics, L., Karadi, I., *Anti-cholesterol antibodies (ACHA) in patients with different atherosclerotic vascular diseases and healthy individuals. Characterization of human ACHA*. *Atherosclerosis*, 2001. **156**: p. 185-192.

References

212. Perez-Guzman, C., Vargas, M.H., *Hypocholesterolemia: A major risk factor for developing pulmonary tuberculosis?* Med Hypotheses, 2006. **66**: p. 1227–1230.
213. Van der Meer-Janssen, Y.P.M., van Galen, J., Batenburg, J.J., Helms, J.B., *Lipids in host–pathogen interactions: Pathogens exploit the complexity of the host cell lipidome.* Prog Lipid Res, 2009. **49**: p. 1-26.
214. De Hostos, E.L., *The coronin family of actin-associated proteins.* Trends Cell Biol, 1999. **9**: p. 345-349.
215. Deghmane, A., Soualhine, H., Bach, H., Sendide, K., Itoh, S., Tam, A., Noubir, S., Talal, A., Lo, R., Toyoshima, S., Av-Gay, Y., Hmama, Z., *Lipoamide dehydrogenase mediates retention of coronin-1 on BCG vacuoles, leading to arrest in phagosome maturation.* J Cell Sci, 2007. **120**: p. 2796-2806.
216. Trimble, W.S., Grinstein, S., *TB or not TB: Calcium regulation in mycobacterial survival.* Cell, 2007. **130**: p. 12-14.
217. Beukes, M., Lemmer, Y., Deysel, M., Al Dulayymi, J.R., Baird, M., Koza, G., Iglesias, M.M., Rowles, R.R., Theunissen, C., Grooten, J., Toschi, G., Roberts, V.V., Pilcher, L., Van Wyngaardt, S., Mathebula, N., Balogun, M., Stoltz, A.C., Verschoor, J.A., *Structure-function relationships of the antigenicity of mycolic acids in tuberculosis patients.* Chem Phys Lipids, 2010: p. doi:10.1016/j.chemphyslip.2010.09.006.